Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Patients 13-18 y.o.

NCT03206346 Phase 3 COMPLETED

The purpose of this study is to determine whether Ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.

Details

Lead sponsor	Valenta Pharm JSC
Phase	Phase 3
Status	COMPLETED
Enrolment	161
Start date	2012-01
Completion	2013-08

Conditions

• Influenza, Human
• Acute Respiratory Infection
• Viral Infection
• Common Cold

Interventions

• Ingavirin
• Placebo oral capsule

Primary outcomes

• Time to resolution of fever — 7 ± 1 days
  Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС)

Countries

Russia